The JCA Comparator Gap has become one of the most consequential structural features of Europe’s new clinical assessment process. The first Joint Clinical Assessments under EU Regulation 2021/2282 have not produced a single, ready-to-use evidence package. A shared European starting point still leaves substantial national translation work. For leaders in health economics, market access and pricing strategies, the practical issue is how this incomplete multi-PICO output should reshape development timing, value demonstration and reimbursement decisions.

A shared checkpoint that stops short of decision-ready evidence

Member States set out their preferred standards of care during scoping. Those preferences are then folded into one broad assessment scope. Manufacturers therefore face more comparators than any single national process would normally ask for, often without direct head-to-head data. Indirect comparisons become necessary, and they attract close methodological scrutiny. The resulting European report is open about its own limits. It rarely gives national bodies the clear comparative conclusion they need for final appraisal. The pattern shows up across the earliest published assessments and has direct consequences for system dynamics and budget impact planning.

Early reports examined by LCP and others reveal the same shortfall. In the tovorafenib assessment for paediatric low-grade glioma, eight PICOs were generated across three populations. Comparative data were supplied for only two. One unanchored matching-adjusted indirect comparison was kept but heavily discounted, because of residual confounding and an effective sample size of roughly six patients. A second was excluded. Six PICOs could not be addressed at all. Other initial dossiers have similar partial coverage. When multi-PICO scoping meets incomplete comparative evidence, the JCA Comparator Gap is the expected result, and the early dossiers show it repeatedly.

Where the JCA Comparator Gap reaches beyond the European report

Health economics teams still need a credible clinical anchor for cost-effectiveness and budget impact models. When several PICOs remain unanswered, national submissions have three options: narrow the decision question, run new analyses that may diverge from the European text, or accept higher uncertainty. Payers tend to price that uncertainty conservatively. Value-based pricing discussions lose force when the only nominally significant progression-free survival signal favours the comparator, or when it rests on methods that major agencies reject.

National divergence makes the problem sharper. An ISPOR Europe analysis of recent G-BA decisions found comparator misalignment to be the leading reason for “additional benefit not proven” outcomes, accounting for 57 percent of cases. Both the G-BA and HAS apply stricter filters than the JCA itself, particularly on unanchored methods and the need for full individual patient data. An indirect comparison that appears, with caveats, in the European package can still be set aside or re-run at country level. Pricing strategies and reimbursement decisions in major markets therefore still turn on local evidence strength. The mere existence of a Joint Clinical Assessment does not change that.

The effects reach beyond individual submissions. Incomplete comparative packages slow confidence in displacing current regimens and complicate pathway redesign and long-term resource allocation. Companies working across regions face an added tension: an evidence plan stretched to satisfy a wide European scope may still leave important non-EU markets under-prepared if their preferred comparators were never anticipated. The same principle of comparator relevance applies whenever local practice diverges from the consolidated PICO list.

Turning diagnosis into practical mitigation

Remap Consulting outlines a workable three-phase response once the JCA package exists. First, map the European evidence against local requirements in priority markets and separate clinical from economic comparators. Second, rank the residual gaps according to their true effect on appraisal success, price potential and access. Third, choose targeted mitigation (further indirect comparisons, subgroup work, refined economic modelling or selective local evidence generation) and test those choices with payers before full submission. Earlier PICO forecasting remains the highest-leverage preventive step. Testing likely national standards of care against the planned Phase III package, while the design can still change, turns many later surprises into managed decisions.

Recommendations for decision-makers

HEOR and clinical development leaders should build comparator strategy into asset planning, rather than treating it as a post-JCA compliance task. For every anticipated PICO, record an explicit choice: direct evidence, a feasible indirect comparison with pre-arranged data access, alternative support, or a deliberately accepted gap whose access and budget impact consequences have already been modelled. Market access directors need dual European-plus-national value narratives that acknowledge JCA limitations without letting those limitations set the national price ceiling. Pricing strategists should stress-test launch forecasts against the realistic chance that the indirect comparisons a dossier relies on will be discounted in Germany and France. HTA bodies and policymakers could reduce avoidable delay by setting out in advance when JCA-accepted methods will be revisited, and by discouraging the nomination of low-relevance comparators during scoping.

Strategic outlook

The JCA Comparator Gap shows that European clinical convergence has not removed the need for sophisticated national translation. It has made the missing pieces visible earlier. Organisations that treat the Joint Clinical Assessment as the finish line will keep finding fixed evidence constraints at the moment of greatest commercial exposure. Those that treat comparator choice as a development decision, secure data access early and run flexible dual-track plans will turn the same incomplete package into more predictable reimbursement decisions and more defensible pricing strategies. Further alignment on methodological tolerances and tighter scoping discipline would still improve system efficiency. Until then, early evidence planning is the surest defence against late surprises.

Frequently asked questions

What is the JCA Comparator Gap?

It is the mismatch between the broad set of comparators in a Joint Clinical Assessment and the comparative evidence manufacturers hold. In the tovorafenib assessment, eight PICOs were generated, comparative data were supplied for only two, and six could not be addressed at all.

Why does the gap matter for pricing and reimbursement?

National bodies still need a comparative conclusion for their own appraisals, and the European report rarely supplies one. The G-BA and HAS apply stricter filters than the JCA, particularly on unanchored methods and the need for full individual patient data, so an indirect comparison in the European package can still be set aside or re-run at country level.

What can companies do about it?

Map the European evidence against local requirements in priority markets, rank the residual gaps by their effect on appraisal success, price potential and access, and choose targeted mitigation. Earlier PICO forecasting is the highest-leverage preventive step. It means testing likely national standards of care against the planned Phase III package while the design can still change.